Frontiers in oncology2026ReviewDrug Delivery
Beaugé L, Ibarra Le
Photo-assisted therapies have emerged as promising strategies for cancer treatment by combining localized tumor ablation with the induction of systemic antitumor immune responses. Despite encouraging preclinical and clinical advances, their therapeutic efficacy remains limited by the unfavorable pharmacokinetics…
Read the article →Translational research : the journal of laboratory and clinical medicine2026ReviewDrug Delivery
Kausar T, Ahmed W, Shafiq T, Kausar R, Liang Y, Duan L
Nanomedicine represents one of the pivotal technologies that further bridges critical gaps in precision theranostics through targeted delivery, integrated diagnostics and therapeutics, and personalized treatment. Among various nanocarriers, extracellular vesicles (EVs) have attracted substantial interest owing to…
Read the article →International journal of nanomedicine2026ReviewDrug Delivery
Li X, Yu Y, Xie Y, He P, Chen Y, Guo Z, Et Al.
Macrophages are highly plastic immune cells with tumor-homing capacity and immunomodulatory functions, making macrophage-based nanoplatforms attractive for cancer immunotherapy. Macrophage-based nanoplatforms include macrophage-derived extracellular vesicles (EVs), macrophage membrane-coated nanoparticles, and live…
Read the article →Advances in Colloid and Interface Science2026ReviewNon-viral Gene DeliveryDrug Delivery
D Zhi, A Halemaimaiti, B Dai, H Li, H Wang, Z Zhang, J Yu, S Zhang
This review examines how lipid structure and formulation affect the delivery of DNA, mRNA and siRNA by lipid nanoparticles, while assessing tissue targeting, safety and clinical translation challenges.
Read the article →BioDrugs2026ReviewNon-viral Gene DeliveryDrug Delivery
U Iqbal, Rw Hwang, Wj Costain
A review of blood–brain barrier transport mechanisms and emerging lipid nanoparticle strategies for carrying nucleic acid and other complex therapies into the central nervous system.
Read the article →Small2025ReviewNon-viral Gene DeliveryDrug Delivery
S Sarmah, S Baidya, M De
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Read the article →Molecular Therapy Methods & Clinical Development2025ReviewNon-viral Gene Delivery
Ca Brimacombe, Ja Kulkarni, Mhy Cheng, K An, D Witzigmann, Pr Cullis
A review of the physical principles and development history behind siRNA lipid nanoparticles for liver gene silencing and mRNA lipid nanoparticles for protein expression.
Read the article →Nature Reviews Drug Discovery2024ReviewNon-viral Gene DeliveryDrug Delivery
Pr Cullis, Pl Felgner
This historical review traces lipid-based gene delivery from cationic lipoplexes to ionisable lipid nanoparticles, connecting foundational research with approved mRNA vaccines and siRNA therapy.
Read the article →Advanced Materials2024ReviewNon-viral Gene Delivery
Cm Jogdeo, K Siddhanta, A Das, L Ding, S Panja, N Kumari, D Oupický
A review of polymer-based alternatives to lipid gene delivery, including polyplexes and polymer–nucleic acid conjugates, with attention to chemical tunability and clinical translation.
Read the article →2023ReviewNon-viral Gene Delivery
Pinto Is, Cordeiro Ra, Faneca H
CAR T cell therapy is FDA/EMA-approved for B cell malignancies and multiple myeloma, but manufacturing relies on viral vectors—associated with safety concerns, high cost, and production challenges—or electroporation, which can be highly cytotoxic. Nanosystems may offer a safer, cost-effective alternative, but T cells…
Read the article →Biomaterials Science2022ReviewNon-viral Gene Delivery
Sydney R. Shannon, Elena Ben-Akiva, Jordan J. Green
Gene therapies are transforming treatment for many diseases, but clinical efficacy and safety depend on both the delivery material and the cargo. Non-viral delivery to immune cells remains especially challenging, and no clinical translation breakthrough has yet been achieved for non-viral gene editing. This…
Read the article →Acta Pharmaceutica Sinica B2022ReviewNon-viral Gene Delivery
Yingping Zeng, Sufen Li, Shufen Zhang, Li Wang, Hong Yuan, Fuqiang Hu
Cancer immunotherapy is limited by tumour heterogeneity, immune cell disability, immunosuppressive tumour microenvironment (TME), and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) offer a biomimetic delivery strategy that inherits source-cell functions—immune evasion, tumour targeting, and…
Read the article →Frontiers in Oncology2022ReviewNon-viral Gene Delivery
Tianqing Xin, Li Cheng, Chuchao Zhou, Yimeng Zhao, Zhenhua Hu, Xiaoyan Wu
CAR-T cell therapy has shown impressive success in haematological malignancies, but systemic toxicity (CRS, ICANS, on-target/off-tumour effects) and the complex, costly, individualized manufacturing process of autologous CAR-T cells hinder broader application. Universal allogeneic CAR-T cells have encountered safety…
Read the article →Science Advances2022ReviewNon-viral Gene Delivery
Ann E. Metzloff, Margaret M. Billingsley, Michael J. Mitchell
mRNA vaccines have entered global use, but delivering mRNA to T cells in vivo remains challenging because T cells are non-phagocytic, reside largely in lymphoid tissues, and intravenously administered lipid nanoparticles (LNPs) tend to accumulate in the liver. There is a need for precise, scalable strategies to…
Read the article →Signal Transduction and Targeted Therapy2022ReviewNon-viral Gene Delivery
Qin S, Tang X, Chen Y, Et Al.
mRNA therapeutics have fuelled hope to combat incurable diseases, but insufficient understanding of mRNA instability, immunogenicity, and delivery has impeded progress. The review argues that mRNA-based drugs—especially after the COVID-19 vaccine success—can become powerful, versatile tools, and that mRNA…
Read the article →2022ReviewDrug Delivery
Lei W, Yang C, Wu Y, Ru G, He X, Tong X, Wang S.
Conventional chemotherapy suffers from poor targeting and severe side effects, while synthetic nanocarriers are often cleared by the immune system and lack precise tumour targeting. Cell membrane-coated nanocarriers (CMCNs) offer a biomimetic strategy to improve biocompatibility, immune evasion, circulation time, and…
Read the article →2022ReviewNon-viral Gene Delivery
Chuang St, Conklin B, Stein Jb, Pan G, Lee K-B.
Immunotherapy has improved outcomes in cancer and infectious disease, but off-target effects, systemic toxicities, and variable efficacy remain limiting. Nanoscale engineering offers ways to manipulate immune cell functions—enhancing immunity against cancers and pathogens, controlling the site of immune response, and…
Read the article →Materials Today Advances2022ReviewNon-viral Gene Delivery
Randall A. Meyer, Sarah Y. Neshat, Jordan J. Green, Jose Luis Santos, And Anthony D. Tuesca
mRNA gene therapy has broad therapeutic potential (protein replacement, vaccines, regenerative medicine, oncology), but clinical translation is limited by inadequate understanding of how to target specific organs or cell types for protein expression. Reports on material properties and administration routes are…
Read the article →European Journal of Medicinal Chemistry2022ReviewNon-viral Gene Delivery
Mingyuan Li, Yuan Li, Shiqin Li, Lin Jia, Haomeng Wang, Meng Li, Jie Deng, Ali Zhu, Liqiao Ma, Weihong Li, Peng Yu, And Tao Zhu
The COVID-19 pandemic has greatly accelerated the application of mRNA technology, demonstrating its unique advantages over traditional biopharmaceutical and vaccine technology. However, mRNA instability in human physiological environments and inefficient in vivo delivery remain major barriers. mRNA chemical…
Read the article →Advanced Healthcare Materials2022ReviewNon-viral Gene Delivery
Erin W. Kavanagh And Jordan J. Green
Viral vectors dominate gene therapy but suffer from immunogenicity, insertional mutagenesis risk, cargo-size limits, and manufacturing challenges. Non-viral nanoparticles are safer, more economical, and easier to scale, but their clinical translation has been limited by inefficient delivery, especially for DNA and…
Read the article →Heart Failure Reviews (Springer)2022ReviewNon-viral Gene Delivery
Paolo Morfino, Alberto Aimo, Vincenzo Castiglione, Carolina Galvez-Montón, Michele Emdin, Antoni Bayes-Genis
Cardiac fibrosis contributes to the pathogenesis of heart failure, myocardial infarction, and arrhythmias, but no primarily anti-fibrotic drug has been approved for cardiovascular disease. Many candidate anti-fibrotic strategies have shown promise in preclinical models yet failed to demonstrate clear clinical…
Read the article →Molecules2022ReviewNon-viral Gene Delivery
Wang H-L, Wang Z-G, Liu S-L
mRNA is a promising cancer immunotherapy platform for vaccines, cytokines, costimulatory receptors, and therapeutic antibodies, but it is unstable, immunogenic, and poorly delivered in vivo. Safer and more efficient delivery systems are needed to improve mRNA stability, cellular uptake, endosomal escape, and…
Read the article →2022ReviewNon-viral Gene Delivery
Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M
RNA-loaded lipid nanoparticles (LNPs) are clinically validated for siRNA and mRNA delivery, but their therapeutic performance depends critically on reproducible control of size, size distribution, zeta potential, and RNA encapsulation efficiency. Microfluidic devices offer precise mixing, rapid ethanol dilution, high…
Read the article →Journal of Pharmaceutical Investigation.2022ReviewNon-viral Gene Delivery
Karmacharya P, Patil Br, Kim Jo
mRNA is an attractive platform for cancer immunotherapy, but its instability, susceptibility to RNase degradation, and inefficient endosomal escape limit therapeutic applications. Lipid-based nanocarriers are non-viral vectors that can protect mRNA, improve transfection, and deliver it to intracellular compartments…
Read the article →